Article
Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
Molecular cancer therapeutics - 1 Feb 2015
Suryani Santi, Bracken Lauryn S, Harvey Richard C, Sia Keith C S, Carol Hernan, Chen I-Ming, Evans Kathryn, Dietrich Philipp A, Roberts Kathryn G, Kurmasheva Raushan T, Billups Catherine A, Mullighan Charles G, Willman Cheryl L, Loh Mignon L, Hunger Stephen P, Houghton Peter J, Smith Malcolm A, Lock Richard B
Abstract excerpt
Genome-wide studies have identified a high-risk subgroup of pediatric acute lymphoblastic leukemia (ALL) harboring mutations in the Janus kinases (JAK). The purpose of this study was to assess the preclinical efficacy of the JAK1/2 inhibitor AZD1480, both as a single agent and in combination with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.